

# 1 **Effects of a novel infant formula on weight gain and body composition** 2 **of infants: The INNOVA 2020 study**

3 **Julio Plaza-Diaz<sup>1,2,3,#</sup>, Francisco Javier Ruiz-Ojeda<sup>1,2,4,5,#</sup>, Javier Morales<sup>6</sup>, Ana Isabel Cristina**  
4 **de la Torre<sup>7</sup>, Antonio García-García<sup>8,9</sup>, Carlos Nuñez de Prado<sup>10</sup>, Cristóbal Coronel<sup>11</sup>, Cyntia**  
5 **Crespo<sup>11</sup>, Eduardo Ortega<sup>12</sup>, Esther Marín-Pérez<sup>13</sup>, Fernando Ferrerira<sup>14</sup>, Gema García-Ron<sup>15</sup>,**  
6 **Ignacio Galicia<sup>8</sup>, María Teresa Santos-García-Cuéllar<sup>8</sup>, Marcos Moroto<sup>8</sup>, Paola Ruiz<sup>16</sup>, Raquel**  
7 **Martín<sup>17</sup>, Susana Viver-Gómez<sup>18</sup> and Angel Gil<sup>1,2,5,19,\*</sup>**

8 <sup>1</sup>Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada,  
9 18071, Granada, Spain

10 <sup>2</sup>Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de  
11 Granada, Granada 18014, Spain

12 <sup>3</sup>Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada.

13 <sup>4</sup>RG Adipocytes and Metabolism, Institute for Diabetes and Obesity, Helmholtz Diabetes Center at  
14 Helmholtz Center Munich, Neuherberg, 85764 Munich, Germany.

15 <sup>5</sup>Institute of Nutrition and Food Technology "José Mataix", Centre of Biomedical Research,  
16 University of Granada, Avda. del Conocimiento s/n. 18016 Armilla, Granada, Spain

17 <sup>6</sup>Product Development Department, Alter Farmacia SA, 28880 Madrid, Spain.

18 <sup>7</sup>CS Presentación sabio. C/Alonso Cano 8, 28933 Móstoles, Madrid

19 <sup>8</sup>Instituto Fundación Teófilo Hernando (IFTH). Parque científico de Madrid. UAM.. C/ Faraday 7.  
20 Edificio CLAUD. 28049. Madrid.

21 <sup>9</sup>Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid,  
22 Spain

23 <sup>10</sup>Consulta Privada Carlos Nuñez, C/Santiago Apóstol 10, 28220 Majadahonda, Madrid, Spain

24 <sup>11</sup>CS Amante Laffón. Pz San Martín de Porres 8, 41010, Sevilla.

25 <sup>12</sup>CAP Nova Lloreda, Av. De Catalunya 62-64, 08917 Badalona, Barcelona.

26 <sup>13</sup>CS Parque Loranca, C/ de la Alegría 2, 28942 Fuenlabrada, Madrid

27 <sup>14</sup>Consulta Externa Hospital Privado Santa Ángela de la Cruz, Av. De Jerez 59, 41013, Sevilla.

28 <sup>15</sup>CS La Rivota. C/ de las Palmeras s/n, 28922 Alcorcón, Madrid.

29 <sup>16</sup>CS Las Américas, Av. De América 6, 28983 Parla, Madrid.

30 <sup>17</sup>CS Doctor Luengo Rodríguez, C/ Nueva York 16, 28938 Móstoles, Madrid.

31 <sup>18</sup>CS Valle de la Oliva. C/ Enrique Granados 2, 28222 Majadahonda, Madrid.

32 <sup>19</sup>CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III,  
33 28029 Madrid, Spain

34 #Equally contributed

35 \* **Correspondence:**

36 Prof. Angel Gil

37 Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada,  
38 Campus de Cartuja s/n, 18071, Granada, Spain

39 Phone: +34 695466922

40 agil@ugr.es

#### 41 **Abstract**

42 **Background:** Breastmilk is the most appropriate food for infants and exclusive breastfeeding is  
43 highly recommended for the first six months of life to promote adequate growth and development  
44 and lower infant morbidity and mortality. Among the best-documented benefits of breastfeeding is  
45 the reduced risk of disease and infections such as pneumonia, diarrhea and acute otitis media.  
46 Nonetheless, there are situations in which the infant cannot be breastfed; therefore, it is essential to  
47 use an appropriately designed infant formula. As current infant formulas incorporate novel  
48 ingredients to partly mimic the composition of human milk, the safety and suitability of each specific  
49 infant formula should be tested by clinical evaluation in the target population. Here, we report the  
50 results of a multicenter, randomized, blinded, controlled clinical trial that aimed to evaluate a novel  
51 starting formula on weight gain and body composition of infants up to 6 and 12 months (INNOVA  
52 2020 study), as well as safety and tolerability. The complete protocol of this study has been  
53 previously issued. **Study design:** 210 infants (70/group) were enrolled in the study, and completed  
54 the intervention until 12 months of age. For the intervention period, infants were divided into three  
55 groups: group 1 received the formula 1 (Nutribén® Innoval or INN), with a lower amount of protein,  
56 and enriched in  $\alpha$ -lactalbumin protein, and with a double amount of docosahexaenoic acid (DHA)/  
57 arachidonic acid (ARA) than the standard formula; it also contained a thermally inactivated  
58 postbiotic (*Bifidobacterium animalis* subsp. *lactis*, BPL1™ HT). Group 2 received the standard  
59 formula or formula 2 (Nutriben® Natal or STD) and the third group was exclusively breastfed for  
60 exploratory analysis and used as a reference (BFD group). During the study, visits were made at 21  
61 days, 2, 4, 6, and 12 months of age, with  $\pm$  3 days for the visit at 21 days of age,  $\pm$  1 week for the  
62 visit at 2 months, and  $\pm$  2 weeks for the others. During the first 6 months of the study, the infants  
63 were only supplied with the starting formula or natural breastfeeding. **Results:** The primary outcome,  
64 weight gain, was higher in both formula groups than in the BFD group at 6 and 12 months, whereas  
65 no differences were found between STD and INN groups neither at 6 nor at 12 months. Likewise,  
66 BMI was higher in infants fed the two formulas compared with the BFD group. Regarding body  
67 composition, length, head circumference and tricipital/subscapular skinfolds were alike between  
68 groups. The INN formula was considered safe as weight gain and body composition were within the  
69 normal limits, according to WHO standards. The BFD group exhibited more liquid consistency in the  
70 stools compared to both formula groups. All groups showed similar digestive tolerance and infant  
71 behavior. However, a higher frequency of gastrointestinal (GI) symptoms was reported by the STD  
72 formula group (291), followed by the INN formula (282) and the BFD groups (227). There were  
73 fewer respiratory, thoracic, and mediastinal disorders among BFD children. Additionally, infants  
74 receiving the INN formula experienced significantly fewer general disorders and disturbances than

75 those receiving the STD formula. Indeed, atopic dermatitis, bronchitis, and bronchiolitis were  
76 significantly more prevalent among infants who were fed the STD formula compared to those fed  
77 INN formula or breastfed. To evaluate whether there are significant differences between formula  
78 treatments, beyond growth parameters, it would seem necessary to examine more precise health  
79 biomarkers and to carry out long-term longitudinal studies.

80 **Clinical Trial Registration:** The trial was registered with Clinicaltrial.gov (NCT05303077) on  
81 March 31, 2022, and lastly updated on April 7, 2022.

82 **Keywords:** Arachidonic acid (ARA);  $\alpha$ -lactalbumin; *Bifidobacterium animalis* subsp. *lactis*,  
83 BPL1<sup>TM</sup>; body composition; docosahexaenoic acid (DHA); infant formula; postbiotics: protein;  
84 safety.

## 85 1.- Introduction

86 Exclusive breastfeeding is the gold standard for infant feeding because it promotes adequate growth  
87 and development, excellent nutritional status, and appropriate psychological development. In  
88 addition, due to the special composition of breast milk in bioactive and immunogenic substances, it  
89 effectively protects against numerous infectious diseases, mainly pneumonia and other respiratory  
90 infections, diarrhea, and allergic processes. Moreover, breastfeeding promotes an optimal psycho-  
91 affective mother-child relationship and has a very low cost, practically nil (Ip et al., 2009; Walker,  
92 2010; Black et al., 2013; Victora et al., 2016; Ogbu et al., 2021). Indeed, WHO and UNICEF  
93 recommend starting breastfeeding within the first hour of birth and being exclusively breastfed for  
94 the first 6 months of life (World Health Organization, 2002; 2022). However, from the age of 6  
95 months, children should begin eating safe and adequate complementary foods while continuing to  
96 breastfeed for up to 2 years and beyond (Kramer and Kakuma, 2001).

97 Breastfeeding protects against disease in both developing (Black et al., 2013) and developed  
98 countries (Ip et al., 2009) and is beneficial not only for infants but also for mothers. Indeed,  
99 breastfeeding may protect later in life against obesity and metabolic diseases (Rameez et al.,  
100 2019; World Health Organization, 2022). Additionally, breastfeeding is associated with better  
101 performance on intelligence tests (Horta et al., 2015; Victora et al., 2015). Furthermore, women who  
102 breastfeed have a reduced risk of breast and ovarian cancers (World Health Organization, 2022).

103 Despite worldwide efforts to promote breastfeeding, there are many social factors, especially  
104 premature return to work after childbirth and, in some cases, maternal illness, which cause many  
105 mothers to abandon breastfeeding prematurely (Balogun et al., 2015). To promote the adequate  
106 growth and development of general infants and those who have those conditions, infant formula  
107 designed with an optimal nutritional composition is essential. In this regard, different entities such as  
108 the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)  
109 (Koletzko et al., 2005) and the American Academy of Paediatrics (AAP) have established various  
110 recommendations for the composition of infant formulas. In addition, various governmental  
111 organizations, such as the FAO/WHO Codex Alimentarius Commission (CODEX ALIMENTARIS,  
112 2020), the European Union Commission (Commission Delegated Regulation (EU) 2016) and the US  
113 Food and Drug Administration (FDA) (FOOD AND DRUG ADMINISTRATION, 2018) have  
114 established strict compositional and control standards for infant formula foods to protect the health of  
115 consumers and ensure fair practices in the food trade.

116 Continuous research on the composition of human milk and the biological effects of its components  
117 (Christian et al., 2021) has led to the constant evolution of infant formula, especially during the last

118 five decades, incorporating various food ingredients to meet not only the nutritional needs of infants  
119 but also to contribute to better development and functionality (Carver, 2003). Thus, based on certain  
120 studies suggesting that a high protein intake in the early stages of life may be the cause of obesity and  
121 increased risk of metabolic disease in later stages of life (Brands et al., 2014;Zheng et al., 2018), the  
122 protein composition of infant formulas has been adjusted both in quality and quantity, reducing the  
123 protein intake of infants (Weber et al., 2014; Totzauer et al., 2018;Kouwenhoven et al., 2021).  
124 Regarding the quality of protein intake, the whey/casein ratio in infant formulas is important for the  
125 first year of life. Whey proteins, both  $\beta$ -lactoglobulin and  $\alpha$ -lactalbumin, are rapidly digested and  
126 participate in the building of muscle mass (Boirie et al., 1997), being the  $\alpha$ -lactalbumin the major  
127 protein in human milk (Liao et al., 2017). Therefore, development of infant formula containing  
128 bovine  $\alpha$ -lactalbumin may improve the plasma amino acid pattern of the receiver infant, allowing a  
129 reduction in the protein content of the formula. On the other hand, the relatively high content of long-  
130 chain polyunsaturated fatty acids of both the n-6 and n-3 series, especially arachidonic acid (AA,  
131 20:4 n-6) and docosahexaenoic acid (DHA, 22:6 n-3) in human milk and their proven effects on the  
132 cognitive development of infants, has led to the incorporation of these fatty acids into infant  
133 formulas. In this regard, and even though EFSA and the European Union Commission have  
134 established mandatory compositional recommendations only for DHA content (EFSA Panel on  
135 Dietetic Products and Allergies, 2014;EU Commission, 2016), numerous researchers have argued  
136 and established consensus documents on the need for infant formulas to incorporate both AA and  
137 DHA in amounts comparable to the average composition of human milk. Hence, according to some  
138 studies infant formula should provide DHA at levels of 0.3% to 0.5% by weight of total fatty acids  
139 and with a minimum level of ARA equivalent to the DHA content (Koletzko et al., 2020;Campoy et  
140 al., 2021). Therefore, the supplementation of infant formulas with both DHA and ARA in appropriate  
141 amounts should be clinically tested.

142 During the last two decades, advances in the knowledge of the composition of the intestinal  
143 microbiome of breast-fed infants and its beneficial effects on the host (Flaherman et al.,  
144 2018;Gopalakrishna and Hand, 2020) have led to the incorporation of both prebiotics and probiotics  
145 in infant formulas (Thomas et al., 2010;Braegger et al., 2011). In this regard, improvements in the  
146 prevention of acute infectious diarrhea, treatment of antibiotic-associated diarrhea and prevention of  
147 allergy have been reported (Thomas et al., 2010;Braegger et al., 2011;Szajewska et al.,  
148 2016;Adjibade et al., 2022). Also, it is known that not only live probiotics but also their fermentation  
149 products and death cells derived from inactivated probiotics, referred to by the International  
150 Scientific Association of Probiotics and Prebiotics (ISAPP) as postbiotics, can exert biological  
151 effects of interest on the intestinal microbiota (Salminen et al., 2021;Vinderola et al., 2022). In this  
152 context, *Bifidobacterium animalis* subsp. *lactis* CECT 8145 inactivated by heat (BPL1<sup>TM</sup> HT)  
153 exhibits several biological effects of interest such as reduction in fat deposition via the IGF-1  
154 pathway in mice (Balaguer et al., 2022) and has anti-obesity effects in obese Zucker rats (Carreras et  
155 al., 2018). Moreover, daily consumption of the living strain BPL1<sup>TM</sup> ameliorates several  
156 anthropometric adiposity biomarkers in abdominally obese adults (Pedret et al., 2019). Likewise, an  
157 infant formula supplemented with BPL1<sup>TM</sup> HT reduced fat deposition in *C. elegans* and augmented  
158 acetate and lactate in a fermented infant slurry (Silva et al., 2020).

159 Novel infant formulas should be thoroughly evaluated to ensure their safety, efficacy, and  
160 tolerability. Hence, in the present study, we aimed to evaluate the effect of a novel starting infant  
161 formula on weight gain, body composition, safety, and tolerability, in infants up to 6 and 12 months  
162 of age. This was compared with standard infant formula. Safety and tolerability outcomes included  
163 digestive tolerance (flatulence, vomiting and regurgitation), stool appearance (consistency and  
164 frequency), behavior (restlessness, colic, nocturnal awakenings), and incidence of infections. Safety

165 objectives included any frequency of GI symptoms resulting from the consumption of the study  
166 formula. As a further exploratory objective, we compared weight gain up to 6 and 12 months and  
167 changes in the other secondary outcomes among the infants who received the modified starter  
168 formula and the standard formula with a group of exclusively breastfed infants. The complete design  
169 and methodology of this randomized, multicenter, double-blind, parallel, comparative clinical trial  
170 has been previously registered with Clinicaltrials.gov (NCT05303077) on March 31, 2022, and lastly  
171 updated on April 7, 2022, and published (Ruiz-Ojeda et al., 2022).

172

## 173 **2.- Material and methods**

### 174 2.1. Ethics

175 This clinical trial was carried out following the recommendations of the International Conference on  
176 Harmonization Tripartite on PCBs, the ethical-legal principles established in the latest revision of the  
177 Declaration of Helsinki, as well as the current regional regulations that regulate pharmacovigilance  
178 and food safety. The present study was approved by the Committee for Technical Investigation in  
179 Regional Medicine in the Madrid Community (CEIm-R) dated 11/05/2018 under the name  
180 INNOVA2020 version 2.0. All personal data obtained in this study are confidential. They were  
181 treated under the Spanish Organic Law 3/2018, of December 5, on the Protection of Personal Data  
182 and guarantee of digital rights. The researchers or the institutions implicated in the study allowed  
183 direct access to the data or source documents for monitoring, auditing, and review by the CEIm-R.  
184 They also allowed inspection of the trial by the health authorities.

### 185 2.2. Trial design

186 The INNOVA study was designed as a randomized, multi-center, double-blind, parallel, and  
187 comparative clinical trial of the equivalence of two starting infant formulas for infants. Furthermore,  
188 a third un-blinded group of breastfed infants was used as a further reference group for exploratory  
189 analysis. Blinding for both investigator and participant remained assured as both infant formulas  
190 were labeled the same. It is not mandatory to carry out specific clinical tests to demonstrate the  
191 nutritional and healthy properties of infant formulas as per the current EU legislation (EC Regulation  
192 No. 1924/2006) (Ruiz-Ojeda et al., 2022).

193 Parents were informed by pediatricians involved in the study of the possibility of participating in it at  
194 a meeting at 15 days of infant age. After accepting to participate, they came to the health center for  
195 the baseline visit a week later (visit at 21 days of age). The pediatrician requested, at the meeting at  
196 15 days of life, that parents provide at the next visit relevant information from the maternal history  
197 that was required for the study and that was not available in the pediatric history. The visit that took  
198 place within the scheduled time was considered valid with a margin of  $\pm 3$  days in the visit at 21 days  
199 of age,  $\pm 1$  week in the visit at 2 months of age, and  $\pm 2$  weeks in visits at 4, 6 and 12 months of age.  
200 The inclusion criteria were healthy children of both sexes; term children (between 37 and 42 weeks  
201 of gestation), birth weight between 2500-4500 g, single delivery, and mothers with a body mass  
202 index, before pregnancy, between 19 and 30 kg/m<sup>2</sup>. The exclusion criteria were, body weight less  
203 than the 5<sup>th</sup> percentile for that gestational age at the time of the inclusion, allergy to cow's milk  
204 proteins and/or lactose, history of antibiotic use during the 7 days before inclusion, congenital disease  
205 or malformation that can affect growth, diagnosis of disease or metabolic disorders, significant  
206 prenatal and/or severe postnatal disease before enrollment, minor parents (younger than 18 years  
207 old), newborn of a diabetic mother, newborn of a mother with drug dependence during pregnancy,

208 newborn whose parents/caregivers cannot comply with procedures of the study, and infants  
209 participating or have participated in another clinical trial since their birth. Participants had the right to  
210 withdraw from the study at any time and for any reason, without giving explanations or suffering any  
211 penalty for it. Likewise, the investigator could withdraw study participants if they did not comply  
212 with the study procedures. This is for any reason that, in the investigator's opinion, may pose the  
213 infants at risk or makes it necessary to suspend breastfeeding. Children who received antibiotics  
214 during the 7 days before inclusion were not considered eligible for the study and, children who  
215 received antibiotics during the trial, were excluded: Any treatment, food or product that could  
216 interfere with the trial at any time, and breastfeeding which was different from that of the group  
217 assigned group in the trial.

218 The sample size of the trial is 210 children (70/group), based on the main outcome of weight gain,  
219 which is the main variable chosen according to the guidelines "Guidelines from the American  
220 Academy of Pediatrics Task Force on Clinical Testing of Infant Formulas" (Task force on clinical  
221 testing of infant formulas committee on nutrition. American Academy of Pediatrics Committee on  
222 Nutrition et al., 1988). The infants were selected by Primary Care pediatricians through active and  
223 consecutive recruitment i.e. pediatricians informed and invited parents of 15-day-old infants not  
224 being breastfed for some reasons to be involved in the trial (see details below under item 2.3). The  
225 study was carried out in 21 centers, all located in Spain, of which 17 recruited at least one subject. In  
226 total, 217 subjects signed the informed consent (IC) and 145 were randomized to receive one of the  
227 two infant formulas. Of these 145, 3 were randomization failures and 2 were screening failures, thus  
228 140 infants who met all the inclusion criteria and no exclusion criteria were included in the study,  
229 and 70 were unblinded within infants exclusively breastfed. A total of 185 subjects completed all  
230 study visits, of which there were 25 dropouts, 12 in the breastfeeding group, 8 in the formula 1 group,  
231 and 5 in the standard formula group. The trial was registered with clinicaltrials.gov website  
232 (NCT05303077, <https://clinicaltrials.gov/ct2/show/NCT05303077>) on March 31, 2022, and lastly  
233 updated on April 7, 2022 (Ruiz-Ojeda et al., 2022). The inclusion period started in October 01, 2018;  
234 and the follow-up period was between February 11, 2019 and November 25, 2020.

### 235 2.3 Formula characteristics

236 •Group 1 (Infant formula 1): Nutribén® Innova 1

237 •Group 2 (Infant formula 2): Nutribén® Standard

238 •Group 3: Breastfeeding (External control exploratory analysis)

239 Infants were recruited from Primary Care Pediatrics clinics by the pediatricians participating in the  
240 trial. Pediatricians informed and invited parents of 15-day-old infants who visited their offices  
241 regularly (for regular medical check-ups) to be involved in the trial. Infants that not receive  
242 breastfeeding at the time of inclusion (for different reasons) were proposed to participate in the  
243 formula-feeding groups. To keep the three arms of the trial balanced, one candidate breastfeeding  
244 subject was recruited at each center for every two infants supplemented with infant formula. The  
245 selection of the children was made among those infants who met the inclusion and exclusion criteria  
246 of the study and fit the categories of sex, body mass index (BMI) of the mother before pregnancy  
247 (<25 kg/m<sup>2</sup> or >25 kg/m<sup>2</sup>), and birth weight (<3500 g or >3500 g).

248 The experimental product object of this trial (Formula 1 or Nutribén® Innova 1, INN formula) and  
249 the Nutribén® Standard formula (STD formula) comply with the recommendations of the  
250 ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology and Nutrition) and with

251 Regulation 609/2013 of the European Parliament and of the Council regarding foods intended for  
 252 children, infants and young children, foods for special medical purposes and complete diet substitutes  
 253 for weight control and repealing Council Directives 92/51, Directives 96/8/EC, 1999/21/CE,  
 254 2006/125/CE and 2006/141/CE of the Commission, Directive 2009/38/CE of the European  
 255 Parliament and of the Council and Regulations 41/2009 and 953/2009 of the Commission. More  
 256 detailed information on the composition of each of the products can be found in Table 1. Infant  
 257 formulas are given ad libitum orally. The two trial formulations were administered following the  
 258 preparation instructions in the manufacturer’s package insert. DHA was obtained from purified and  
 259 concentrated fish oil.

260

261 **Table 1.** Nutritional composition of the standard infant formula (STD) and study formula (INN).

Composition	STD formula			INN formula		
	100 g	100 mL	100 kcal	100 g	100 mL	100 kcal
Energy (kcal)	514	67		489	67	
Energy (kJ)	2152	280		2046	279	
Total Fat (g)	27	3.5	5.2	25.6	3.5	5.2
Linoleic acid ( $\square$ -6) (mg)	3.79	493	736	3.147	427	641
$\alpha$ -linolenic acid ( $\square$ -3) (mg)	500	65	97	387	53	79
Arachidonic acid AA ( $\square$ -6) (mg)	53	6.9	10	118	16	24
Docosahexaenoic acid DHA ( $\square$ -3) (mg)	53	6.9	10	118	16	24
Carbohydrates (g)	56.4	7.3	11	54.6	7.4	11.1
Total sugars (g)	56.4	7.3	11	53	7.2	10.8
Lactose (g)	55	7.2	10.7	53	7.2	10.8
Galacto-oligosaccharides (g)	3.1	0.4	0.6	2.9	0.4	0.6
Proteins (g)	10.6	1.4	2.1	9.4	1.3	1.9
Whey proteins (g)	6.4	0.83	1.2	6.6	0.9	1.3
Caseins (g)	4.2	0.55	0.82	2.8	0.38	0.57

262 2.4 Measurements and evaluations

263 2.4.1 Anthropometric measures

264 Weight, length, head circumference, body mass index, body fat percentage, and lean body mass  
 265 measurements were taken at all study visits (*visit 1*, 21 days, *visit 2*, 2 months, *visit 3*, 4 months, *visit*  
 266 *4*, 6 months, and *visit 5*, 12 months). Fat mass was estimated by the skinfold measurements. From the  
 267 visit scheduled for the fourth month of life, the mean arm circumference, the triceps skinfold, and the  
 268 subscapular skinfold were added to the previous measurements. All these measurements were done in  
 269 duplicate. Using as valid data the mean between the two. Each center had all the necessary materials  
 270 to carry out these measurements. They needed to always use the same material with all subjects and,  
 271 of course, the material should be calibrated.

272 2.4.2 Characteristics of feces and digestive tolerance

273 We evaluated consistency and the number of stools/day) at times 21 days, 2, 4, 6 and 12 months of  
274 age Flatulence, vomiting and regurgitation at times 21 days, 2, 4, 6 and 12 months of age were also  
275 assessed.

#### 276 2.4.3 Infant's behavior evaluated by parents

277 Restlessness, colic, and night awakenings were evaluated during 21 days, 2, 4, 6 and 12 months of  
278 age for the parents. More details are available in the study protocol (Ruiz-Ojeda et al., 2022).

#### 279 2.4.4 Morbidity, safety and tolerability

280 Variables related to morbidities were evaluated within 1-year. All morbidities were coded according  
281 to MedDRA dictionary version 21.0 (MedDRA, 2018).

### 282 2.5 Statistical methods

283 The main objective of the study was to evaluate whether the weight gain was equivalent between  
284 treatment groups receiving formula 1 and 2, and it has been decided that the sample size of the trial is  
285 210 children (70/group) based on the primary variable weight gain (the primary variable selected),  
286 following the "Guidelines from the American Academy of Pediatrics" issued by the Task Force on  
287 Clinical Testing of Infant Formulas of the American Academy of Pediatrics (Task force on clinical  
288 testing of infant formulas committee on nutrition. American Academy of Pediatrics Committee on  
289 Nutrition et al., 1988). Previous studies carried out on children fed from 0 to 6 months with different  
290 formulations of infant formula have shown a mean weight gain of around 20-25 g/day with a  
291 standard deviation between 5 and 6 g/day (Bosheva et al., 2022). In most of these studies, a  
292 difference in mean weight gain of 3 g/day was considered clinically relevant. Thus, the main  
293 objective was resolved by using a t-test for independent samples. Considering a power of 80%, a  
294 significance level of 5%, an equivalence limit of 3 g/day, and a common standard deviation of 5.5  
295 g/day, we needed to recruit at least 59 children in each of the groups. Based on an estimated dropout  
296 rate of 20%, it was necessary to include 70 children in each of the groups, which means 140 infants.  
297 A third group of the same size (70 children) was included for the secondary comparisons between the  
298 bottle-fed and breastfed groups, maintaining the same significance and power in this secondary  
299 comparison as in the main comparison. Categorical variables are described as frequencies or  
300 percentages. Continuous variables are reported as mean and standard deviation. Between-group  
301 differences in measures of growth and body composition are analyzed using analysis of variance,  
302 including analysis of covariance and general models of analysis of variance for repeated measures  
303 (GLM-ANOVA and MANOVA) when required. The Chi-square test is applied to compare discrete  
304 variables between groups. The Bonferroni correction is used when comparisons are made between  
305 more than two groups. The alpha level of significance is set at 0.05. All evaluable infants have been  
306 included in the statistical analysis, considering "evaluable" all those who have the main measurement  
307 variable. Both, intention to treat and protocol-based statistical analyses are performed.

### 308 3.- Results

309 **Table 2** shows demographic and descriptive information for infants and their mothers. Here,  
310 gestational age, birth weight, childbirth delivery, assisted reproductive technology, and the mother's  
311 medical background were included, though no significant variables were shown. During visit 1 (21  
312 days), only daily depositions per day were significantly higher for the BFD group in comparison with  
313 formula groups.



314 The parents or legal guardians returned to the center all the leftover containers (empty containers and  
 315 containers with products) to record the amount of product dispensed and the amount of infant  
 316 formula used up to the time of the visit; the corresponding weighing was performed and the  
 317 percentage of product ingested by the participants was determined. Finally, the grams of formulation  
 318 consumed by each infant, measured by weighing the leftover formulations or as indicated in the  
 319 parents' diary corresponding to the periods between visits 1-2, 2-3 and 3-4, were available. The  
 320 participants of this study included in the formula-feeding groups were considered compliant if they  
 321 took at least 80% of the formula during the first six months while in the breastfeeding group it was  
 322 considered a valid external control if more than 80% of the feedings were breastfeeding. All infants  
 323 included in the BFD group, except one, consumed more than 80% of human milk during the first six  
 324 months.

325 Based on the record of the amount of product dispensed and the amount of infant formula used  
 326 (measurement of leftover) we estimated the average daily intake from visits 1 to 4 for the STD group  
 327 ( $130.2 \pm 14.7$  g/d, equivalent to  $671 \pm 76$  kcal/d of energy and  $13.8 \pm 1.56$  g/d of protein) and the INN  
 328 group ( $134.0 \pm 18.2$  g/d, equivalent to  $655 \pm 89$  kcal /d of energy and  $12.60$  g/d of protein).

329 A GLM-ANOVA was performed for grams of formula consumed per day, and significant differences  
 330 were observed for visit, sex and infant birth weight, but not about the formula used (data not  
 331 presented).

332 **Table 2.** Baseline demographics of the infants in the study

	<b>BFD</b>	<b>STD</b>	<b>INN</b>	<b>P-value</b>
<b>N</b>	70	70	70	
<b>Gender (% of women)</b>	28 (40.0)	29 (41.4)	33 (47.1)	0.738
<b>Gestational age (weeks)</b>	39.44 (1.1)	39.20 (1.1)	39.34 (0.9)	0.389
<b>Birth weight (g)</b>	3359.20 (403.9)	3300.87 (462.9)	3363.30 (408.7)	0.626
<i>Birth weight &gt;3500 g (%)</i>	22 (31.4)	22 (31.4)	27 (38.6)	0.613
<b>Childbirth delivery n, (%)</b>				0.579
<i>Cesarean section</i>	13 (18.6)	17 (24.3)	20 (28.6)	
<i>Distocyc</i>	8 (11.4)	6 (8.6)	9 (12.9)	
<i>Normal childbirth</i>	49 (70.0)	47 (67.1)	41 (58.6)	
<b>Assisted reproductive technology n, (%)</b>	4 (5.7)	6 (8.6)	3 (4.3)	0.679
<i>Assisted reproductive technology type (%)</i>				0.066
<i>In vitro fertilization</i>	1 (25.0)	6 (100.0)	2 ( 66.7)	
<i>Artificial insemination</i>	2 (50.0)	0 (0.0)	1 ( 33.3)	
<i>Egg donation</i>	1 (25.0)	0 (0.0)	0 (0.0)	
<b>Maternal BMI (kg/m<sup>2</sup>), (x, SD)</b>	23.72 (3.2)	23.92 (3.3)	23.78 (3.0)	0.967
<i>BMI mother &gt;25 n, (%)</i>	22 ( 31.4)	22 ( 31.4)	24 ( 34.3)	0.85
<b>Mother's medical background n, (%)</b>				0.849
<i>Allergy</i>	0 (0.0)	0 (0.0)	2 (2.9)	
<i>Hypothyroidism</i>	7 (10.0)	5 (7.1)	4 (5.7)	
<i>Arterial hypertension</i>	0 (0.0)	2 (2.9)	1 (1.4)	
<i>No</i>	58 (82.9)	55 (78.6)	55 (78.6)	

<i>Others</i>	5 (7.1)	8 (11.4)	8 (11.4)	
<b>Visit 1, (21 days)</b>	<b>BFD</b>	<b>STD</b>	<b>INN</b>	<b>P-value</b>
<b>Depositions per day</b>	5.2 (3.2)	2.5 (2.0)	2.3 (1.4)	<0.001*
<b>Weight</b>	3921.8 (475.5)	3805.0 (507.5)	3916.6 (453.9)	0.268
<b>Length</b>	53.1 (1.9)	52.6 (2.2)	52.8 (1.7)	0.287
<b>Head circumference</b>	36.6 (1.0)	36.2 (1.3)	36.5 (1.2)	0.214

333 Data are expressed as mean and standard deviation, and frequency or percentage. BMI, body mass index; NS, non-significant

334 **Table 3. Differential daily weight gain and absolute weight in the entire study**

Differential daily weight gain per day (g)						
Groups	BFD	STD	INN		P-value	
Differential daily weight gain	(N=58)	(N=65)	(N=62)	STD vs. BFD	INN vs. BFD	STD vs. INN
Visit 4 vs Visit 1	22.0 ± 4.6	24.24 ± 5.06	24.60 ± 5.29	0.01	0.004	0.693
Visit 5 vs visit 1	16.01 ± 2.66	17.41 ± 3.25	17.00 ± 2.95	0.011	0.057	0.457
Weight (g)						
Groups	BFD	STD	INN		P-value	
Weight	(N=58)	(N=65)	(N=62)	Formula	Visit	Formula x visit
<b>Visit 1, 21 days</b>	3951.3 ± 498.0	3805.8 ± 509.6	3916.9 ± 468.7			
<b>Visit 2, 2 months</b>	5285.1 ± 564.9	5193.7 ± 684.0	5236.6 ± 623.2			
<b>Visit 3, 4 months</b>	6558.6 ± 697.1	6733.0 ± 937.7	6843.1 ± 855.1	0.081	0.848	0.011
<b>Visit 4, 6 months</b>	7471.1 ± 846.3	7718.7 ± 1132.8	7903.1 ± 1063.5			
<b>Visit 5, 12 months</b>	9505.2 ± 985.6	9869.7 ± 1382.1	9797.6 ± 1234.4			

335 Data are expressed as mean ± standard deviation

336 The primary variable (weight gain) consisted of the difference in infant weight (in g/day) between the  
337 initial recruitment visit and the 6-month visit, divided by the number of days between the two visits.  
338 This analysis was performed on the 187 infants who completed until visit 4 (6 months). The  
339 difference between visit 1 and visit 4 was calculated in days of 187 children individually (**Table 3**).  
340 When analyzing the mean difference in weight gain between the groups of children treated with the  
341 STD and INN formulations (**Table 3**), there was no statistically significant difference in weight gain  
342 between the two formulations. On the other hand, an ANOVA of the weight difference between visits  
343 1 and 4 was performed for the STD and INN formulations controlling for the factors, gender,  
344 maternal body mass index (BMI) and birth weight. There were significant differences in weight  
345 difference between visits 1 and 4 as a function of gender and infant birth weight, but not as a function  
346 of formulation or mother's BMI (**Table 3**). The grams consumed per day were also related to the  
347 difference in weight between visits 1 and 4. Based on the weighing of leftover grams of the dispensed  
348 formulation, a multivariate analysis of variance (MANOVA) of the difference in weight of the  
349 children between visits 1 and 4 was performed as a function of formulation consumed (STD, INN),  
350 gender (male, female), maternal BMI (<25, >25), birth weight (<3500, >3500) and grams ingested  
351 per day. A moderate positive correlation (r=0.535) was observed between mean grams ingested per  
352 day (measured by weighing leftover formulations) and weight gain between visits 1 and 4 of the  
353 infants. This correlation changed significantly by gender (males achieved larger weight differences  
354 for the same daily grams of formulation consumed) and by birth weight (infants with birth weights >  
355 3500 g achieved larger weight differences for the same daily grams of formulation consumed) but not  
356 as a function of maternal BMI or formulation used.

357 This same MANOVA as a function of grams ingested daily according to the parental diary also  
 358 showed a positive correlation ( $r=0.626$ ) between mean grams ingested per day (obtained from  
 359 parental diary entries) and weight gain between visits 1 and 4 of the infants. This correlation changed  
 360 significantly by gender (boys achieved larger weight differences for the same daily grams of  
 361 formulation consumed) and by birth weight (children with birth weights  $> 3500$  achieved larger  
 362 weight differences, especially those who consumed more daily grams of formulation) but not as a  
 363 function of maternal BMI or formulation used.

364 Secondly and foreseen in the study protocol, the weight gain of the infants who received each of  
 365 the formulations studied was compared with the BFD group. The results of this analysis are shown in  
 366 **Table 3**, where it can be seen that BFD infants had a significantly lower weight gain at 6 months of  
 367 age than that shown by infants fed with either of the two formulations evaluated (STD and INN).

368 The same analysis was performed for the variable weight gain at 12 months of study. **Table 3** shows  
 369 the number of children in each of the 3 groups studied with weight values recorded at visit 1 (21 days  
 370 of age) and visit 5 (12 months  $\pm 2$  weeks). A comparison of the means of weight gain from the  
 371 different formulations (STD vs. INN, STD vs. BFD and, INN vs. BFD, **Table 3**) revealed that at 6  
 372 months there is no significant difference in weight gain (measured in g/day) as well as at 12 months  
 373 between the STD and INN formulations. The total weight of the STD formulation group remained  
 374 significantly higher than the BFD group at 12 months, however, the INN group exhibited a trend to  
 375 be different from breastfeeding between visits 1 and 5 ( $p=0.057$ ). A GLM-ANOVA (data not  
 376 presented) showed significant differences for visit ( $p<0.001$ ) and for the interaction between  
 377 formulation and visit ( $p=0.004$ ), but not for formulation exclusively ( $p=0.381$ ). The largest effect size  
 378 was associated with the visit factor.

379 **Table 4.** Length and head circumference in the entire study

Length (cm)			
Visits	<b>BFD</b> (N=58)	<b>STD</b> (N=65)	<b>INN</b> (N=62)
<b>Visit 1</b>	53.15 $\pm$ 2.08	52.49 $\pm$ 2.24	52.87 $\pm$ 1.78
<b>Visit 2</b>	57.89 $\pm$ 2.42	57.47 $\pm$ 2.33	57.95 $\pm$ 2.02
<b>Visit 3</b>	63.16 $\pm$ 2.42	63.24 $\pm$ 3.67	63.50 $\pm$ 2.16
<b>Visit 4</b>	66.68 $\pm$ 2.64	67.01 $\pm$ 3.26	67.15 $\pm$ 2.14
<b>Visit 5</b>	75.44 $\pm$ 2.90	75.82 $\pm$ 3.08	75.96 $\pm$ 2.54
Head circumference (cm)			
Visits	<b>BFD</b> (N=58)	<b>STD</b> (N=65)	<b>INN</b> (N=62)
<b>Visit 1</b>	36.66 $\pm$ 1.02	36.22 $\pm$ 1.34	36.51 $\pm$ 1.25
<b>Visit 2</b>	36.09 $\pm$ 1.17	38.87 $\pm$ 1.36	39.11 $\pm$ 1.63
<b>Visit 3</b>	41.56 $\pm$ 1.12	41.79 $\pm$ 3.73	41.64 $\pm$ 1.39
<b>Visit 4</b>	43.19 $\pm$ 1.22	43.18 $\pm$ 1.37	43.41 $\pm$ 1.45
<b>Visit 5</b>	46.40 $\pm$ 1.18	46.25 $\pm$ 1.53	46.29 $\pm$ 1.50

380 Data are expressed as mean and standard deviation

381 No significant differences were observed in length and head circumference, as well as, tricipital and  
 382 subscapular skinfolds and mean upper arm circumference (**Tables 4 and 5**).

383  
 384  
 385  
 386

387  
388  
389

**Table 5.** Tricipital and subscapular skinfolds and mean upper arm circumference in visits 3, 4, and 5.

	Tricipital skinfold (mm)		
	<b>BFD</b>	<b>STD</b>	<b>INN</b>
	<b>(N=58)</b>	<b>(N=65)</b>	<b>(N=62)</b>
<b>Visit 3</b>	12.32 ± 2.26	12.66 ± 2.67	12.78 ± 3.00
<b>Visit 4</b>	12.35 ± 2.23	12.60 ± 2.65	12.90 ± 2.99
<b>Visit 5</b>	12.34 ± 2.23	12.63 ± 2.65	12.84 ± 2.99
	Subscapular skinfold (mm)		
	<b>BFD</b>	<b>STD</b>	<b>INN</b>
	<b>(N=58)</b>	<b>(N=65)</b>	<b>(N=62)</b>
<b>Visit 3</b>	9.92 ± 2.69	9.83 ± 2.72	10.25 ± 2.73
<b>Visit 4</b>	9.90 ± 2.49	9.94 ± 2.72	10.36 ± 2.73
<b>Visit 5</b>	9.91 ± 2.58	9.89 ± 2.73	10.30 ± 2.72
	Mean upper arm circumference (cm)		
	<b>BFD</b>	<b>STD</b>	<b>INN</b>
	<b>(N=58)</b>	<b>(N=65)</b>	<b>(N=62)</b>
<b>Visit 3</b>	13.79 ± 1.30	13.89 ± 1.67	14.15 ± 1.21
<b>Visit 4</b>	14.41 ± 1.24	14.72 ± 1.46	14.98 ± 1.88
<b>Visit 5</b>	15.34 ± 1.26	15.29 ± 1.68	15.94 ± 1.39

390  
391

Data are expressed as mean and standard deviation

**Table 6.** Body mass index, body fat percentage, and lean mass.

Visits	Body mass index (kg/m <sup>2</sup> )			Formula	P-value	
	<b>BFD</b> <b>(N=58)</b>	<b>STD</b> <b>(N=65)</b>	<b>INN</b> <b>(N=62)</b>		Visit	Formula x visit
<b>Visit 1</b>	13.94 ± 1.11	13.75 ± 1.04	13.97 ± 1.07			
<b>Visit 2</b>	15.74 ± 1.08	15.67 ± 1.30	15.56 ± 1.28			
<b>Visit 3</b>	16.42 ± 1.22	16.97 ± 3.61	16.94 ± 1.59	0.487	<0.001	<0.001
<b>Visit 4</b>	16.78 ± 1.30	17.15 ± 1.83	17.49 ± 1.81			
<b>Visit 5</b>	16.69 ± 1.28	17.11 ± 1.64	16.94 ± 1.54			
Visits	Body fat percentage			Formula	P-value	
	<b>BFD</b> <b>(N=58)</b>	<b>STD</b> <b>(N=65)</b>	<b>INN</b> <b>(N=62)</b>		Visit	Formula x visit
<b>Visit 3</b>	19.35 ± 3.53	19.60 ± 3.39	20.37 ± 3.67			
<b>Visit 4</b>	20.36 ± 3.53	20.30 ± 3.73	21.29 ± 3.93	0.249	0.005	0.958
<b>Visit 5</b>	20.84 ± 3.64	21.02 ± 3.82	21.61 ± 4.01			
Visits	Lean mass (g)			Formula	P-value	
	<b>BFD</b> <b>(N=58)</b>	<b>STD</b> <b>(N=65)</b>	<b>INN</b> <b>(N=62)</b>		Visit	Formula x visit
<b>Visit 3</b>	5284 ± 559	5403 ± 709	5436 ± 615			
<b>Visit 4</b>	5942 ± 654	6135 ± 823	6207 ± 782	0.215	<0.001	0.054
<b>Visit 5</b>	7509 ± 703	7805 ± 1023	7670 ± 967			

392

Data are expressed as mean and standard deviation

393 In the case of BMI, the ANOVA (**Table 6**) shows significant differences for visit (p<0.001) and for  
394 the interaction between formulation and visit (p<0.001), but not for formulation (p=0.487). The  
395 largest effect size was associated with the visit factor (0.4230, data not provided). In addition, we

396 have reported that it was from the third visit onwards that the mean BMI was higher in the STD and  
 397 INN formulations compared to the BFD group; hence, the interaction effect appears as significant  
 398 (**Table 6**). For the body fat percentage, the ANOVA (**Table 6**) shows significant differences for visit  
 399 ( $p=0.005$ ), but not for the interaction between formulation and visit ( $p=0.958$ ) and for formulation  
 400 ( $p=0.249$ ). The largest effect size is associated with the visit factor (0.0236, data not shown). Finally  
 401 for the lean mass, the ANOVA (**Table 6**) shows significant differences for visit ( $p<0.001$ ), but not  
 402 for the interaction between formulation and visit ( $p=0.054$ ) and for formulation ( $p=0.215$ ). The  
 403 largest effect size is associated with the visit factor (0.6093, data not provided).

404 In the case of BMI percentiles, the ANOVA (**Table S1**) reveals significant differences for visit  
 405 ( $p=0.009$ ) and the interaction between formulation and visit ( $p=0.006$ ), but not for formulation  
 406 ( $p=0.504$ ). The largest effect size is associated with the visit factor (0.0222, data not provided). In  
 407 the ANOVA, there were significant differences in the height percentiles for visit ( $p=0.011$ ), for the  
 408 interaction between formulation and visit ( $p<0.001$ ), but not for formulation ( $p=0.433$ , **Table S1**).  
 409 The largest effect size is associated with the visit factor (0.0154, data not shown). Finally, in the  
 410 weight percentiles, the ANOVA (**Table S1**) shows significant differences for visit ( $p<0.001$ ) and for  
 411 the interaction between formulation and visit ( $p<0.001$ ), but not for formulation ( $p=0.368$ ). The  
 412 largest effect size is associated with the visit factor (0.0228, data not provided).

413 The time course of the study shows a difference between breastfed infants presenting stools of a more  
 414 liquid consistency (**Table S2**), although these differences ceased to be significant at visit 5 (see **table**  
 415 **S2**). Likewise, the daily number of stools was higher in breastfed infants at visits 1, 2 and 3, but these  
 416 differences ceased to be significant at visits 4 and 5 (**Table 7**).

417 **Table 7.** The daily number of stools.

Number of daily depositions	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
BFD					
<b>Mean (SD)</b>	5.2 (3.2)	3.1 (2.3)	2.3 (1.5)	2.0 (1.4)	1.8 (1.0)
<b>Median [Min, Max]</b>	5 [3, 8]	3 [1, 4]	2 [1, 3]	2 [1, 2]	2 [1, 2]
STD					
<b>Mean (SD)</b>	2.5 (2.0)	1.5 (0.7)	1.3 (0.6)	1.5 (1.0)	1.9 (0.9)
<b>Median [Min, Max]</b>	2 [1, 4]	1 [1, 2]	1 [1, 2]	1 [1, 2]	2 [1, 2]
INN					
<b>Mean (SD)</b>	2.3 (1.4)	1.6 (0.8)	1.6 (0.9)	1.6 (0.9)	1.9 (0.8)
<b>Median [Min, Max]</b>	2 [1, 3]	1 [1, 2]	1 [1, 2]	1 [1, 2]	2 [1, 2]

418 Data are expressed as mean and maximum and minimum

419 **Figure 1** shows the tabulation of the different categories of digestive tolerance between every two  
 420 visits. An increase in the percentage of children with high tolerance is seen throughout the study  
 421 without significant differences between the different formulations and compared with the BFD  
 422 group.


423

424

425

426

427 **Figure 1**



440 **Figure 1. Digestive tolerance.** Data are presented as percentages (%). BFD, breastfeeding group;  
 441 STD, standard group; INN, INNOVA group.

442 The infant's behavior was re-coded as altered mood or pleasant mood according to the guardians or  
 443 parents. **Table S3** shows how the percentage of infants with altered behavior decreased throughout  
 444 the study. No significant differences were observed among the three ways of feeding.

445 The study found no differences in tolerability between the different groups (**Table S4**). According to  
 446 the safety of the different formulations, the majority of the adverse events (n=754) were mild - Grade  
 447 1 (94.3%), 13 were moderate-Grade 2 (1.6% of the total) and none were severe-Grade 3. The  
 448 intensity was not recorded for 33 of the events (4.1%) (**Table 8**). There were no differences between  
 449 the different groups concerning the intensity of the events. For example, there were 93.0% of mild  
 450 events in the BFD group, 91.8% in the INN group, and 97.6% in the STD group.

451 **Table 8.** Gastrointestinal symptoms across the study

Total adverse events	BFD (N=70)	STD (N=70)	INN (N=70)
Subjects with at least one adverse event (%)	62 (88.6%)	57 (81.4%)	61 (87.1%)
Total number	227	291	282
Mild - Grade 1	211	284	259
Moderate - Grade 2	3	3	7
Severe - Grade 3	0	0	0

Potentially fatal - Grade 4	0	0	0
Lethal - Grade 5	0	0	0
Unknown	13	4	16
<b>Adverse events related to feeding</b>	<b>BFD (N=70)</b>	<b>STD (N=70)</b>	<b>INN (N=70)</b>
Subjects with at least one adverse event (%)	1 (1.4%)	1 (1.4%)	1 (1.4%)
Total number	1	2	2
Mild - Grade 1	1	2	2
Moderate -Grade 2	0	0	0
Severe - Grade 3	0	0	0
Potentially fatal - Grade 4	0	0	0
Lethal - Grade 5	0	0	0
Unknown	0	0	0

Data are expressed as counts and percentages

452

453 Most of the gastrointestinal symptoms were mild, with 1 growth failure, within the BFD group that  
 454 led to the introduction of artificial breastfeeding together with breastfeeding, two events, neonatal  
 455 constipation, and abdominal pain, recorded by one infant within the INN group, led to the change of  
 456 formula and the abandonment of the study and two (infantile colic and infant reflux) recorded by one  
 457 infant within the STD group that led to the change of formula and the abandonment of the study  
 458 (**Table 8**).

459 For morbidities that occurred with a frequency greater than 1%, BFD infants exhibited the lowest  
 460 incidence and infants fed INN formula experienced significantly fewer general disorders and  
 461 disturbances compared with the STD group. Indeed, the infants who were fed STD formula had a  
 462 significantly higher incidence of atopic dermatitis, bronchitis and bronchiolitis events than the infants  
 463 who were fed BFD or INN formula. (**Table 9**).

464 **Table 9.** Morbidities that occur with a frequency greater than 1%.

465

MedDRA dictionary version 21.0 (MedDRA, 2018)	BFD (N=70)		STD (N=70)		INN (N=70)	
	Cases	%	Cases	%	Cases	%
Cold	42	18.50	47	16.15	38	13.48
Pyrexia	16	7.05	24	8.25	11	3.90
Bronchitis/Bronchiolitis*	13	5.7	34	11.7	17	6.00
Upper respiratory tract infection	11	4.85	11	3.78	15	5.32
Infantile colic	14	6.17	9	3.09	10	3.55
Conjunctivitis	5	2.20	11	3.78	15	5.32
Neonatal constipation	6	2.64	10	3.44	9	3.19
Acute otitis media	4	1.76	6	2.06	13	4.61
Rhinorrhea	9	3.96	5	1.72	6	2.13
Gastroenteritis	4	1.76	8	2.75	8	2.84
Cough	9	3.96	7	2.41	5	1.77
Vaccination complication	1	0.44	10	3.44	7	2.48
Laryngitis	1	0.44	9	3.09	7	2.48
Atopic dermatitis*	1	0.44	11	3.78	2	0.71
Seborrheic dermatitis	2	0.88	4	1.37	5	1.77

Neonatal diarrhea	2	0.88	3	1.03	5	1.77
Oral candidiasis	4	1.76	3	1.03	2	0.71
Nasopharyngitis	1	0.44	2	0.69	6	2.13
Infantile eczema	1	0.44	5	1.72	2	0.71
Diaper dermatitis	2	0.88	2	0.69	4	1.42
Rash	3	1.32	2	0.69	2	0.71
Neonatal disorder	2	0.88	1	0.34	4	1.42
Upper respiratory tract infection	2	0.88	1	0.34	3	1.06
Wheezing	2	0.88	3	1.03	1	0.35
Infant reflux	1	0.44	2	0.69	3	1.06
Otitis media	4	1.76	1	0.34	1	0.35
Gastroesophageal reflux disease	4	1.76	0	0.00	1	0.35
Heart murmur	4	1.76	1	0.34	0	0.00
Diarrhea	1	0.44	0	0.00	4	1.42
Atopic Dermatitis*	1	0.44	3	1.03	0	0.00
Traumatic head injury	0	0.00	1	0.34	4	1.42
Abdominal pain	0	0.00	1	0.34	3	1.06
Bronchial hyperreactivity	0	0.00	3	1.03	0	0.00
Decreased appetite	0	0.00	3	1.03	0	0.00
Pharyngotonsillitis	0	0.00	1	0.34	3	1.06
Umbilical hernia	0	0.00	1	0.34	3	1.06
Viral rash	0	0.00	1	0.34	3	1.06
Traumatic injury to the mouth	1	0.44	0	0.00	3	1.06
Total			173		246	
						225

466  
467  
468  
469

Data are expressed as counts and percentages, \*p<0.05 BFD and INN vs. STD group. For the analysis, the Chi-square test was used with the Yates correction where appropriate. Bronchitis/bronchiolitis showed a p-value of 0.029 (BFD vs STD), 1.0 (BFD vs INN), and 0.026 (STD vs INN). Atopic dermatitis exhibited a p-value of 0.027 (BFD vs STD), 1.0 (BFD vs INN), and 0.029 (STD vs INN)

#### 470 **4.- Discussion**

471 The present randomized, double-blind, placebo-controlled clinical trial was designed to determine  
472 whether a novel starting infant formula with reduced protein content, lower casein to whey protein  
473 ratio by increasing the content of  $\alpha$ -lactalbumin, influenced weight gain and body composition  
474 compared to a standard formula at 6 and 12 months of age. Furthermore, this product contains higher  
475 levels of DHA and ARA, as well as a postbiotic thermally inactivated (BPL1<sup>TM</sup> HT), compared with  
476 standard infant formula. An exclusively breastfed population was followed-up as a reference. At 6  
477 and 12 months, infants receiving either INN or STD formula gained more weight than the BFD  
478 group, while no difference was observed between STD and INN formulas. BMI was also higher in  
479 infants fed both formulas than in those breastfed. Regarding body composition, length, head  
480 circumference, and tricipital/subscapular skinfolds, we found that all of the measures were similar  
481 between all groups. It is important to note that the INN formula was considered safe based on weight  
482 gain and body composition, which were within the normal limits, according to WHO standards.  
483 Compared to both formulas, BFD produced stools that were more liquid in consistency. Throughout  
484 the study period, all groups exhibited similar digestive tolerance and infant behavior. In terms of the  
485 total number of adverse events reported, the STD formula had the highest number, followed by the  
486 INN formula and finally, the BFD group. However, the majority of them were not related to the type  
487 of feeding. Besides, infants fed either BFD or the INN formula exhibited significantly lower episodes  
488 of atopic dermatitis, bronchitis and bronchiolitis events than those fed the STD formula.



489

490 In addition to exposure to metabolic and endocrine factors during pregnancy (Monasta et al., 2011),  
491 protein intake in formula-fed infants during the first year of life may have a significant impact on  
492 growth later in life and the risk of obesity and metabolic disorders in adulthood (Koletzko et al.,  
493 2009;Zheng et al., 2018). Indeed, the protein content of infant formula is usually greater than that of  
494 human milk to provide all essential amino acids in adequate quantities (Davis et al., 2008). Scientific  
495 evidence indicates that infants fed a formula containing more protein gain more weight during the  
496 first year of life and are heavier at 2 years of age than infants consuming a formula containing less  
497 protein (Koletzko et al., 2009), which reduces the risk of obesity at school age (Weber et al., 2014).  
498 In our RCT, infants fed either INN or STD formula gained more weight than the breastfed group at 6  
499 months as measured by differential daily weight gain per day (g). Similar results have been reported  
500 in other earlier studies (Baird et al., 2008) even with a relatively low content of protein (Timby et al.,  
501 2014). However, previous studies on formulas with a reduced protein-energy ratio of up to 1.8 g/100  
502 kcal have shown more modest differences in growth patterns compared with infants breastfed, similar  
503 to our findings (Räihä et al., 2002;Koletzko et al., 2009;Ren et al., 2022), which supports the  
504 hypothesis that the protein-energy ratio plays a key role for weight gain. In our study the intake of  
505 INN formula was slightly higher than the STD formula, thus compensating for the lower energy  
506 content and protein of the former. Compensation for lower energy density and protein has been  
507 reported in other studies (Timby et al., 2014). After 12 months, the STD group was significantly  
508 higher than BFD and INN groups. We should note that the INN formula contains 8% less protein per  
509 100 kcal than the STD. Thus, in the first six to eight weeks of life, there is almost no difference  
510 between breast milk and formula-fed infants in terms of growth (gain in weight and length). Indeed,  
511 it has been previously reported that formula-fed infants gained weight and length more rapidly than  
512 breast-fed infants from about two months of age to the end of their first year of life (Ziegler, 2006).  
513 Interestingly, the results of a recent review suggest that the difference in weight gain between  
514 formula-fed and breastfed infants is relatively small, comparable, and significantly less than the  
515 nutritionally significant differences used in determining sample size (Wallingford and Barber, 2019).

516 In addition to the total protein content, the whey/casein ratio in infant formulas seems to be important  
517 for the first year of life. Whey proteins, particularly  $\beta$ -lactoglobulin and  $\alpha$ -lactalbumin, are rapidly  
518 digested and participate in the building of muscle mass (Boirie et al., 1997), and particularly,  $\alpha$ -  
519 lactalbumin is the major protein in human milk (Liao et al., 2017). Thus, the addition of bovine  $\alpha$ -  
520 lactalbumin to infant formula modifies the plasma amino acid pattern of the receiver infant, allowing  
521 a reduction in the protein content of the formula. On the other hand, casein proteins are water-  
522 insoluble high molecular weight molecules that are a source of phosphate and calcium in human  
523 milk, because of the highly phosphorylated nature of  $\beta$ -casein and  $\alpha$ -S1-casein, and the requirement  
524 for calcium in forming the aggregates of casein micelles (Poth et al., 2008). Nevertheless, the amount  
525 should be controlled to avoid improper digestion in early life. In this context, using cow's milk as the  
526 protein source in infant formula might result in an  $\alpha$ -casein-dominant formula, which differs from the  
527 whey protein dominance in human milk. Further, bovine whey contains a high concentration of  $\beta$ -  
528 lactoglobulin, which is absent in human milk (Jackson et al., 2004), therefore, adding bovine  $\alpha$ -  
529 lactalbumin to infant formula makes it more similar to that of breastfed infants (Lönnerdal and Lien,  
530 2003). Moreover,  $\alpha$ -lactalbumin is relatively rich in tryptophan, which may result in satisfactory  
531 growth and plasma tryptophan levels similar to those of breastfed infants and infants fed standard  
532 formula (Sandström et al., 2008). Nevertheless, in our study, both formula-fed infants gained weight  
533 more rapidly compared with exclusively breastfed infants, and there was no significant difference  
534 between the groups in terms of length, head circumference, tricipital and subscapular skinfolds, and  
535 upper arm circumference, suggesting that both formulas causes similar body composition in infants.

536 The proportion of fatty acids present in infant formulas is important to ensure the correct growth and  
537 development of infants. In the last 20 years, formulas have been supplemented with LC-PUFA in  
538 amounts similar to breast milk. Despite the new EU regulation that indicates that AA is not needed to  
539 be included, intervention studies assessing the impact of DHA- and AA-supplemented formulas have  
540 resulted in numerous positive developmental outcomes (closer to breast-fed infants) including  
541 measures of specific cognition functions, visual acuity, and immune responses (Forsyth et al.,  
542 2017;Jasani et al., 2017;Lien et al., 2018). AA has different biological functions compared to DHA,  
543 for example, AA has exclusive functions in the vasculature and specific aspects of immunity.  
544 Undeniably, most of the trials include both DHA and AA, and test development specific to DHA  
545 such as neural and visual development. DHA suppresses membrane AA concentrations and its  
546 function. Infant formula with DHA and no AA runs the risk of cardio and cerebrovascular morbidity  
547 and even mortality through suppression of the favorable oxylipin derivatives of AA (Crawford et al.,  
548 2015). International expert consensus suggests that infant formulas that contain DHA at a  
549 concentration of 0.3% to 0.5% by weight of total fat and AA at a minimum level equivalent to the  
550 amount of DHA should be clinically tested (Koletzko et al., 2020;Campoy et al., 2021). In this study,  
551 we used an advanced formula enhanced with a double amount of DHA/AA in comparison with a  
552 STD formula to provide evidence about weight gain and body composition, among other outcomes.  
553 Throughout the study, the percentage of children with high tolerance increased without significant  
554 differences between formulations and compared to the group receiving BFD. According to the  
555 guardians or parents, the infant's behavior was classified as altered mood or pleasant mood. There  
556 was a decrease in the number of infants with altered behavior throughout the study. The three  
557 methods of feeding did not show any significant differences.

558 The INN formula was also supplemented with a thermally inactivated postbiotic *Bifidobacterium*  
559 *animalis* subsp. *lactis*, BPL1<sup>TM</sup> (Carreras et al., 2018;Nataraj et al., 2020), which may confer some  
560 benefits regarding body composition, metabolism, and gut microbiota composition. Probiotics have  
561 many health benefits by modulating the gut microbiome; nonetheless, techno-functional limitations  
562 have made it gradually shift from viable probiotic bacteria towards non-viable postbiotics,  
563 paraprobiotics and/or probiotics-derived biomolecules, so-called postbiotics (Nataraj et al., 2020).  
564 Since the experimental formula of the present study was supplemented with BPL1<sup>TM</sup> HT, it should be  
565 noted that *in vivo* studies reported that this strain can be considered a Generally Recognized as Safe  
566 (GRAS) substance. In terms of the intensity of GI symptoms, tolerability and safety, there were no  
567 differences between the different groups (BFD, STD and INN formula). In different contexts and  
568 using different methods, infants are fed a variety of products. The formula for infants is available in  
569 many variations, many of which are superior to other methods of feeding and some of which are  
570 inferior to others. On the other hand, there was a significant difference between BFD group  
571 presenting stools of a more liquid consistency, although this difference no longer existed at visit five  
572 (12 months). Additionally, BFD infants had more stools per day at visits 1, 2, and 3, but these  
573 differences ceased to be significant at visits 4 and 5. STD formula group reported the most of GI  
574 symptoms, followed by the INN formula and BFD group. There were no differences in safety across  
575 the study between the different groups. Several differences were observed between the two formulas,  
576 showing a significant reduction in general disorders and disturbances among children who received  
577 the INN formula. STD formula-fed infants were more likely to cause atopic dermatitis, bronchitis,  
578 and bronchiolitis than BFD or INN formula-fed infants. Eczema or atopic dermatitis is a common  
579 chronic inflammatory skin disease, mostly occurring in children. Indeed, a meta-analysis showed that  
580 probiotic supplementation during both the prenatal and the postnatal period reduced the incidence of  
581 atopic dermatitis in infants and children, suggesting that starting probiotic treatment during gestation  
582 and continuing through the first 6 months of the infant's life may be of benefit in the prevention of  
583 atopic dermatitis (Li et al., 2019). In this context, a study demonstrated that prenatal and postnatal

584 supplementation with a mixture of *B. bifidum* BGN4, *B. lactis* AD011, and *L. acidophilus* AD031 is  
585 an effective approach in preventing the development of eczema in infants at high risk of allergy  
586 during the first year of life (Kim et al., 2010). Hence, the lower incidence of atopic dermatitis  
587 observed in the INN formula group compared to the STD group might be mediated by the  
588 supplementation of the postbiotic BPL1<sup>TM</sup> HT. Likewise, respiratory tract infections represent one of  
589 the main health problems in children of different ages (Vesa et al., 2001). Finally, changes in the  
590 intestinal microbiota will need to be assessed.

591 There are some limitations for this study. There were no significant correlations between the type of  
592 feeding and the number of adverse events. Nevertheless, the number of infants in the present study  
593 was calculated for the growth as the main variable and not for the morbidity.

594 In conclusion, this clinical trial involved the evaluation of a novel infant formula with reduced  
595 content of total protein and modification of the whey/casein ratio by increasing the content of  $\alpha$ -  
596 lactalbumin, increased levels of both AA and DHA, and postbiotic in comparison with standard  
597 infant formula. For exploratory analysis, a third unblinded group of breastfed infants was used. Both  
598 formulas gained more weight at 6 and 12 months than the BFD group, while no differences were  
599 observed between STD and INN formulas. Infants fed both formulas had a higher BMI than those fed  
600 BFD. Body composition, head circumference, and tricipital/subscapular skinfolds were similar  
601 between the two groups. We should note that the INN formula is safe and it showed a reduction in  
602 atopic dermatitis, bronchitis, and bronchiolitis in infants compared to STD formula. The consistency  
603 of the stools produced by BFD was more liquid in comparison with both formulas. For further  
604 analysis, it would be necessary to examine more precise health biomarkers and to carry out long-term  
605 longitudinal studies.

## 606 **Conflict of Interest**

607 Javier Morales is employee at Alter Farmacia S. A. The remaining authors declare that the research  
608 was conducted in the absence of any commercial or financial relationships that could be construed as  
609 a potential conflict of interest.

## 610 **Author Contributions**

611 AGG, IG and MM were responsible for a careful review of the protocol, design, and methodology.  
612 FJRO, JPD and AG provided continuous scientific advice for the study and the interpretation of the  
613 results. These authors also wrote and critically reviewed the manuscript. All authors approved the  
614 final version of the manuscript.

## 615 **Funding**

616 The present study was funded by Alter Farmacia S. A. The funding sponsor had no role in the design  
617 of the study, the collection, analysis, or interpretation of the data, and the writing of the manuscript.

## 618 **Acknowledgments**

619 We thank to the pediatrician team who participated in this study: Alba Corrales; Alfonso Carmona;  
620 Amalia López; Ana Isabel Rodriguez; Ana Maderuelo; Ana Terrén-Lora; Eduardo Ortega; Esther  
621 Martín; Eva Castillo; Isabel Mayordomo; José Fernando Ferreira; José María Aguilar Diosdado;  
622 Maite Santos-García; Mari Carmen Pino Zambrano; María José Carnicero; María Teresa Santos;  
623 Vasilica Doina and Xavier Riopedre. Julio Plaza-Díaz is part of the “UGR Plan Propio de

624 Investigación 2016” and the “Excellence actions: Unit of Excellence on Exercise and Health  
625 (UCEES), University of Granada”. Julio Plaza-Diaz is supported by a fellowship awarded to  
626 postdoctoral researchers at foreign universities and research centers from the “Fundación Ramón  
627 Areces”, Madrid, Spain.

## 628 **Supplementary Material**

629 Supplementary material is expressed as tables and is found in the supplementary file (Tables S1-S4).

## 630 **Data Availability Statement**

631 The datasets used and/or analyzed during the current study are available from the corresponding  
632 author upon reasonable request.

## 633 **References**

- 634 Adjibade, M., Davaisse-Paturet, C., Divaret-Chauveau, A., Adel-Patient, K., Raheison, C., Dufourg,  
635 M.N., Lioret, S., Charles, M.A., and De Lauzon-Guillain, B. (2022). Enrichment of Formula  
636 in Probiotics or Prebiotics and Risk of Infection and Allergic Diseases up to Age 5.5 Years in  
637 the Nationwide Etude Longitudinale Francaise depuis l'Enfance (ELFE) Cohort. *J Nutr* 152,  
638 1138-1148.
- 639 Baird, J., Poole, J., Robinson, S., Marriott, L., Godfrey, K., Cooper, C., Inskip, H., and Law, C.  
640 (2008). Milk feeding and dietary patterns predict weight and fat gains in infancy. *Paediatr*  
641 *Perinat Epidemiol* 22, 575-586.
- 642 Balaguer, F., Enrique, M., Llopis, S., Barrena, M., Navarro, V., Alvarez, B., Chenoll, E., Ramon, D.,  
643 Tortajada, M., and Martorell, P. (2022). Lipoteichoic acid from *Bifidobacterium animalis*  
644 subsp. *lactis* BPL1: a novel postbiotic that reduces fat deposition via IGF-1 pathway. *Microb*  
645 *Biotechnol* 15, 805-816.
- 646 Balogun, O.O., Dagvadorj, A., Anigo, K.M., Ota, E., and Sasaki, S. (2015). Factors influencing  
647 breastfeeding exclusivity during the first 6 months of life in developing countries: a  
648 quantitative and qualitative systematic review. *Maternal & child nutrition* 11, 433-451.
- 649 Black, R.E., Victora, C.G., Walker, S.P., Bhutta, Z.A., Christian, P., De Onis, M., Ezzati, M.,  
650 Grantham-Mcgregor, S., Katz, J., and Martorell, R. (2013). Maternal and child undernutrition  
651 and overweight in low-income and middle-income countries. *The lancet* 382, 427-451.
- 652 Boirie, Y., Dangin, M., Gachon, P., Vasson, M.P., Maubois, J.L., and Beaufrère, B. (1997). Slow and  
653 fast dietary proteins differently modulate postprandial protein accretion. *Proc Natl Acad Sci*  
654 *U S A* 94, 14930-14935.
- 655 Bosheva, M., Tokodi, I., Krasnow, A., Pedersen, H.K., Lukjancenka, O., Eklund, A.C., Grathwohl,  
656 D., Sprenger, N., Berger, B., Cercamondi, C.I., H.S.I.C., Bauer, V., Arciszewska, M.,  
657 Tarneva, M., Popova, I., Dosev, S., Dimitrova, S., Nikolova, O., Nowak, M., Szuflińska-  
658 Sidorowicz, M., Korczowski, B., Karcheva-Beloeva, R., Banov, S., Cimoszko, B.,  
659 Olechowski, W., Simko, R., Tengelyi, Z., Korbal, P., Zolnowska, M., Bilev, A.,  
660 Vasilopoulos, G., Korzynska, S., Laki, I., Koleva-Syarova, M., Grigorov, T., Kraeva, S.,  
661 Kovács, É., Markova, R., Jasieniak-Pinis, G., Fister, K., and Stoeva, T. (2022). Infant  
662 Formula With a Specific Blend of Five Human Milk Oligosaccharides Drives the Gut  
663 Microbiota Development and Improves Gut Maturation Markers: A Randomized Controlled  
664 Trial. *Frontiers in Nutrition* 9.

- 665 Braegger, C., Chmielewska, A., Decsi, T., Kolacek, S., Mihatsch, W., Moreno, L., Piescik, M.,  
666 Puntis, J., Shamir, R., Szajewska, H., Turck, D., Van Goudoever, J., and Nutrition, E.C.O.  
667 (2011). Supplementation of infant formula with probiotics and/or prebiotics: a systematic  
668 review and comment by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr*  
669 *52*, 238-250.
- 670 Brands, B., Demmelmair, H., Koletzko, B., and Project, E. (2014). How growth due to infant  
671 nutrition influences obesity and later disease risk. *Acta paediatrica* *103*, 578-585.
- 672 Campoy, C., Am, C.T., De La Garza Puentes, A., Sáenz De Pipaón, M., Verduci, E., Koletzko, B.,  
673 Casanova, G., Larqué, E., Valenzuela, R., and Jm, M.V. (2021). Controversy about the  
674 critical role of long-chain polyunsaturated fatty acids, arachidonic acid (ARA) and  
675 docosahexaenoic acid (DHA), during infancy. *Nutricion Hospitalaria*.
- 676 Carreras, N.L., Martorell, P., Chenoll, E., Genoves, S., Ramon, D., and Aleixandre, A. (2018). Anti-  
677 obesity properties of the strain *Bifidobacterium animalis* subsp. *lactis* CECT 8145 in Zucker  
678 fatty rats. *Benef Microbes* *9*, 629-641.
- 679 Carver, J.D. (2003). Advances in nutritional modifications of infant formulas. *The American journal*  
680 *of clinical nutrition* *77*, 1550S-1554S.
- 681 Christian, P., Smith, E.R., Lee, S.E., Vargas, A.J., Bremer, A.A., and Raiten, D.J. (2021). The need  
682 to study human milk as a biological system. *Am J Clin Nutr* *113*, 1063-1072.
- 683 Codex Alimentaris (2020). *STANDARD FOR INFANT FORMULA AND FORMULAS FOR*  
684 *SPECIAL MEDICAL PURPOSES INTENDED FOR INFANTS. Formerly CAC/RS 72-1972.*  
685 *Adopted as a worldwide Standard in 1981. Amended in 1983, 1985, 1987, 2011, 2015, 2016,*  
686 *2020. Revised in 2007.* [Online]. Available: [https://www.fao.org/fao-who-](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252Fstandards%252FCXS%2B72-1981%252FCXS_072e.pdf)  
687 [codexalimentarius/sh-](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252Fstandards%252FCXS%2B72-1981%252FCXS_072e.pdf)  
688 [proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252Fstandards%252FCXS%2B72-1981%252FCXS_072e.pdf)  
689 [%252Fstandards%252FCXS%2B72-1981%252FCXS\\_072e.pdf](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252Fstandards%252FCXS%2B72-1981%252FCXS_072e.pdf) [Accessed 2022-06-12].
- 690 Crawford, M.A., Wang, Y., Forsyth, S., and Brenna, J.T. (2015). The European Food Safety  
691 Authority recommendation for polyunsaturated fatty acid composition of infant formula  
692 overrules breast milk, puts infants at risk, and should be revised. *Prostaglandins Leukot*  
693 *Essent Fatty Acids* *102-103*, 1-3.
- 694 Davis, A.M., Harris, B.J., Lien, E.L., Pramuk, K., and Trabulsi, J. (2008). Alpha-lactalbumin-rich  
695 infant formula fed to healthy term infants in a multicenter study: plasma essential amino acids  
696 and gastrointestinal tolerance. *Eur J Clin Nutr* *62*, 1294-1301.
- 697 Efsa Panel on Dietetic Products, N., and Allergies (2014). Scientific Opinion on the essential  
698 composition of infant and follow-on formulae. *EFSA Journal* *12*, 3760.
- 699 Eu Commission (2016). Commission Delegated Regulation (EU) 2016/127 of 25 September 2015  
700 supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council  
701 as regards the specific compositional and information requirements for infant formula and  
702 follow-on formula and as regards requirements on information relating to infant and young  
703 child feeding. *OJEC* *59*, 1-29.
- 704 Flaherman, V.J., Narayan, N.R., Hartigan-O'connor, D., Cabana, M.D., Mcculloch, C.E., and Paul,  
705 I.M. (2018). The effect of early limited formula on breastfeeding, readmission, and intestinal  
706 microbiota: a randomized clinical trial. *The Journal of pediatrics* *196*, 84-90. e81.

- 707 Food and Drug Administration, F. (2018). *Infant formula requirements pertaining to current good*  
708 *manufacturing practice, quality control procedures, quality factors, records and reports and*  
709 *notifications*. [Online]. Available:  
710 <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=106>  
711 [Accessed 2022-06-12].
- 712 Forsyth, S., Gautier, S., and Salem, N. (2017). The importance of dietary DHA and ARA in early  
713 life: a public health perspective. *Proc Nutr Soc* 76, 568-573.
- 714 Gopalakrishna, K.P., and Hand, T.W. (2020). Influence of Maternal Milk on the Neonatal Intestinal  
715 Microbiome. *Nutrients* 12.
- 716 Horta, B.L., Loret De Mola, C., and Victora, C.G. (2015). Breastfeeding and intelligence: a  
717 systematic review and meta-analysis. *Acta Paediatr* 104, 14-19.
- 718 Ip, S., Chung, M., Raman, G., Trikalinos, T.A., and Lau, J. (2009). A summary of the Agency for  
719 Healthcare Research and Quality's evidence report on breastfeeding in developed countries.  
720 *Breastfeed Med* 4 Suppl 1, S17-30.
- 721 Jackson, J.G., Janszen, D.B., Lonnerdal, B., Lien, E.L., Pramuk, K.P., and Kuhlman, C.F. (2004). A  
722 multinational study of alpha-lactalbumin concentrations in human milk. *J Nutr Biochem* 15,  
723 517-521.
- 724 Jasani, B., Simmer, K., Patole, S.K., and Rao, S.C. (2017). Long chain polyunsaturated fatty acid  
725 supplementation in infants born at term. *Cochrane Database Syst Rev* 3, Cd000376.
- 726 Kim, J.Y., Kwon, J.H., Ahn, S.H., Lee, S.I., Han, Y.S., Choi, Y.O., Lee, S.Y., Ahn, K.M., and Ji,  
727 G.E. (2010). Effect of probiotic mix (*Bifidobacterium bifidum*, *Bifidobacterium lactis*,  
728 *Lactobacillus acidophilus*) in the primary prevention of eczema: a double-blind, randomized,  
729 placebo-controlled trial. *Pediatr Allergy Immunol* 21, e386-393.
- 730 Koletzko, B., Baker, S., Cleghorn, G., Neto, U.F., Gopalan, S., Hernell, O., Hock, Q.S., Jirapinyo, P.,  
731 Lonnerdal, B., Pencharz, P., Pzyrembel, H., Ramirez-Mayans, J., Shamir, R., Turk, D.,  
732 Yamashiro, Y., and Zong-Yi, D. (2005). Global standard for the composition of infant  
733 formula: recommendations of an ESPGHAN coordinated international expert group. *J*  
734 *Pediatr Gastroenterol Nutr* 41, 584-599.
- 735 Koletzko, B., Bergmann, K., Brenna, J.T., Calder, P.C., Campoy, C., Clandinin, M.T., Colombo, J.,  
736 Daly, M., Decsi, T., and Demmelmair, H. (2020). Should formula for infants provide  
737 arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics  
738 and the Child Health Foundation. *The American journal of clinical nutrition* 111, 10-16.
- 739 Koletzko, B., Von Kries, R., Closa, R., Escribano, J., Scaglioni, S., Giovannini, M., Beyer, J.,  
740 Demmelmair, H., Gruszfeld, D., Dobrzanska, A., Sengier, A., Langhendries, J.-P., Rolland  
741 Cachera, M.-F., Grote, V., and European Childhood Obesity Trial Study Group (2009).  
742 Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized  
743 clinical trial. *The American journal of clinical nutrition* 89, 1836-1845.
- 744 Kouwenhoven, S.M.P., Antl, N., Finken, M.J.J., Twisk, J.W.R., Van Der Beek, E.M., Abrahamse-  
745 Berkeveld, M., Van De Heijning, B.J.M., Van Goudoever, J.B., and Koletzko, B.V. (2021).  
746 Long-term effects of a modified, low-protein infant formula on growth and body  
747 composition: Follow-up of a randomized, double-blind, equivalence trial. *Clin Nutr* 40, 3914-  
748 3921.

- 749 Kramer, M., and Kakuma, R. (2001). "The optimal duration of exclusive breastfeeding: a systematic  
750 review. Geneva: World Health Organization, 2001. 47 p". WHO/NHD/01.08).
- 751 Li, L., Han, Z., Niu, X., Zhang, G., Jia, Y., Zhang, S., and He, C. (2019). Probiotic Supplementation  
752 for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-  
753 analysis. *Am J Clin Dermatol* 20, 367-377.
- 754 Liao, Y., Weber, D., Xu, W., Durbin-Johnson, B.P., Phinney, B.S., and Lönnerdal, B. (2017).  
755 Absolute Quantification of Human Milk Caseins and the Whey/Casein Ratio during the First  
756 Year of Lactation. *J Proteome Res* 16, 4113-4121.
- 757 Lien, E.L., Richard, C., and Hoffman, D.R. (2018). DHA and ARA addition to infant formula:  
758 Current status and future research directions. *Prostaglandins Leukot Essent Fatty Acids* 128,  
759 26-40.
- 760 Lönnerdal, B., and Lien, E.L. (2003). Nutritional and physiologic significance of alpha-lactalbumin  
761 in infants. *Nutr Rev* 61, 295-305.
- 762 Meddra, M. (2018). "Introductory Guide for Standardised MedDRA Queries (SMQs) Version  
763 21.0").
- 764 Monasta, L., Batty, G., Macaluso, A., Ronfani, L., Lutje, V., Bavcar, A., Van Lenthe, F., Brug, J.,  
765 and Cattaneo, A. (2011). Interventions for the prevention of overweight and obesity in  
766 preschool children: a systematic review of randomized controlled trials. *Obesity reviews* 12,  
767 e107-e118.
- 768 Nataraj, B.H., Ali, S.A., Behare, P.V., and Yadav, H. (2020). Postbiotics-parabiotics: the new  
769 horizons in microbial biotherapy and functional foods. *Microb Cell Fact* 19, 168.
- 770 Ogbu, C.E., Fongue, S., Ogbu, S.C., and Kirby, R.S. (2021). Infant feeding practices and asthma in  
771 children aged 6 months to 5 years using a propensity score approach. *Cent Eur J Public  
772 Health* 29, 284-289.
- 773 Pedret, A., Valls, R.M., Calderon-Perez, L., Llauro, E., Companys, J., Pla-Paga, L., Moragas, A.,  
774 Martin-Lujan, F., Ortega, Y., Giralt, M., Caimari, A., Chenoll, E., Genoves, S., Martorell, P.,  
775 Codoner, F.M., Ramon, D., Arola, L., and Sola, R. (2019). Effects of daily consumption of  
776 the probiotic *Bifidobacterium animalis* subsp. *lactis* CECT 8145 on anthropometric adiposity  
777 biomarkers in abdominally obese subjects: a randomized controlled trial. *Int J Obes (Lond)*  
778 43, 1863-1868.
- 779 Poth, A.G., Deeth, H.C., Alewood, P.F., and Holland, J.W. (2008). Analysis of the human casein  
780 phosphoproteome by 2-D electrophoresis and MALDI-TOF/TOF MS reveals new  
781 phosphoforms. *J Proteome Res* 7, 5017-5027.
- 782 Rähkä, N.C., Fazzolari-Nesci, A., Cajozzo, C., Puccio, G., Monestier, A., Moro, G., Minoli, I.,  
783 Haschke-Becher, E., Bachmann, C., Van't Hof, M., Carrié Fässler, A.L., and Haschke, F.  
784 (2002). Whey predominant, whey modified infant formula with protein/energy ratio of 1.8  
785 g/100 kcal: adequate and safe for term infants from birth to four months. *J Pediatr  
786 Gastroenterol Nutr* 35, 275-281.
- 787 Rameez, R.M., Sadana, D., Kaur, S., Ahmed, T., Patel, J., Khan, M.S., Misbah, S., Simonson, M.T.,  
788 Riaz, H., and Ahmed, H.M. (2019). Association of Maternal Lactation With Diabetes and  
789 Hypertension: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2, e1913401.

- 790 Ren, Q., Li, K., Sun, H., Zheng, C., Zhou, Y., Lyu, Y., Ye, W., Shi, H., Zhang, W., Xu, Y., and  
791 Jiang, S. (2022). The Association of Formula Protein Content and Growth in Early Infancy: A  
792 Systematic Review and Meta-Analysis. *Nutrients* 14.
- 793 Ruiz-Ojeda, F.J., Plaza-Diaz, J., Morales, J., De La Torre, A.I.C., Garcia-Garcia, A., De Prado, C.N.,  
794 Coronel, C., Crespo, C., Ortega, E., and Martin-Perez, E. (2022). A multicenter, randomized,  
795 blinded, controlled clinical trial investigating the effect of a novel infant formula on the body  
796 composition of infants: INNOVA 2020 study protocol. *medRxiv*.
- 797 Salminen, S., Collado, M.C., Endo, A., Hill, C., Lebeer, S., Quigley, E.M.M., Sanders, M.E., Shamir,  
798 R., Swann, J.R., Szajewska, H., and Vinderola, G. (2021). The International Scientific  
799 Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and  
800 scope of postbiotics. *Nat Rev Gastroenterol Hepatol* 18, 649-667.
- 801 Sandström, O., Lönnerdal, B., Graverholt, G., and Hernell, O. (2008). Effects of alpha-lactalbumin-  
802 enriched formula containing different concentrations of glycomacropeptide on infant  
803 nutrition. *Am J Clin Nutr* 87, 921-928.
- 804 Silva, A., Gonzalez, N., Terren, A., Garcia, A., Martinez-Blanch, J.F., Illescas, V., Morales, J.,  
805 Maroto, M., Genoves, S., Ramon, D., Martorell, P., and Chenoll, E. (2020). An Infant Milk  
806 Formula Supplemented with Heat-Treated Probiotic *Bifidobacterium animalis* subsp. *lactis*  
807 CECT 8145, Reduces Fat Deposition in *C. elegans* and Augments Acetate and Lactate in a  
808 Fermented Infant Slurry. *Foods* 9.
- 809 Szajewska, H., Canani, R.B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., Shamir, R.,  
810 Vandenplas, Y., Van Goudoever, J.B., Weizman, Z., and Probioticsprebiotics, E.W.G.F.  
811 (2016). Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. *J Pediatr*  
812 *Gastroenterol Nutr* 62, 495-506.
- 813 Task Force on Clinical Testing of Infant Formulas Committee on Nutrition. American Academy of  
814 Pediatrics Committee on Nutrition, L, F., Bell Ef, Cooke Rj, Fomon Sj, Kleinman Re,  
815 Pencharz Pb, Reynolds Jw, Schanler Rj, and Al, F. (1988). *Clinical Testing of Infant*  
816 *Formulas With Respect to Nutritional Suitability for Term Infants* [Online]. Available:  
817 [https://wayback.archive-](https://wayback.archive-it.org/7993/20170722090324/https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/InfantFormula/ucm170649.htm)  
818 [it.org/7993/20170722090324/https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocu-](https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/InfantFormula/ucm170649.htm)  
819 [mentsRegulatoryInformation/InfantFormula/ucm170649.htm](https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/InfantFormula/ucm170649.htm) [Accessed 2022-06-24].
- 820 Thomas, D.W., Greer, F.R., American Academy of Pediatrics Committee On, N., American  
821 Academy of Pediatrics Section on Gastroenterology, H., and Nutrition (2010). Probiotics and  
822 prebiotics in pediatrics. *Pediatrics* 126, 1217-1231.
- 823 Timby, N., Domellöf, E., Hernell, O., Lönnerdal, B., and Domellöf, M. (2014). Neurodevelopment,  
824 nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula  
825 supplemented with bovine milk fat globule membranes: a randomized controlled trial. *Am J*  
826 *Clin Nutr* 99, 860-868.
- 827 Totzauer, M., Luque, V., Escribano, J., Closa-Monasterolo, R., Verduci, E., Redionigi, A., Hoyos, J.,  
828 Langhendries, J.P., Gruszfeld, D., Socha, P., Koletzko, B., Grote, V., and European  
829 Childhood Obesity Trial Study, G. (2018). Effect of Lower Versus Higher Protein Content in  
830 Infant Formula Through the First Year on Body Composition from 1 to 6 Years: Follow-Up  
831 of a Randomized Clinical Trial. *Obesity (Silver Spring)* 26, 1203-1210.




- 832 Vesa, S., Kleemola, M., Blomqvist, S., Takala, A., Kilpi, T., and Hovi, T. (2001). Epidemiology of  
833 documented viral respiratory infections and acute otitis media in a cohort of children followed  
834 from two to twenty-four months of age. *Pediatr Infect Dis J* 20, 574-581.
- 835 Victora, C.G., Bahl, R., Barros, A.J., França, G.V., Horton, S., Krasevec, J., Murch, S., Sankar, M.J.,  
836 Walker, N., and Rollins, N.C. (2016). Breastfeeding in the 21st century: epidemiology,  
837 mechanisms, and lifelong effect. *The lancet* 387, 475-490.
- 838 Victora, C.G., Horta, B.L., Loret De Mola, C., Quevedo, L., Pinheiro, R.T., Gigante, D.P.,  
839 Gonçalves, H., and Barros, F.C. (2015). Association between breastfeeding and intelligence,  
840 educational attainment, and income at 30 years of age: a prospective birth cohort study from  
841 Brazil. *Lancet Glob Health* 3, e199-205.
- 842 Vinderola, G., Sanders, M.E., and Salminen, S. (2022). The Concept of Postbiotics. *Foods* 11.
- 843 Walker, A. (2010). Breast milk as the gold standard for protective nutrients. *J Pediatr* 156, S3-7.
- 844 Wallingford, J.C., and Barber, C. (2019). A review of studies on the growth of infants fed infant  
845 formula. *Current Developments in Nutrition* 3, nzz095.
- 846 Weber, M., Grote, V., Closa-Monasterolo, R., Escribano, J., Langhendries, J.P., Dain, E., Giovannini,  
847 M., Verduci, E., Gruszfeld, D., Socha, P., and Koletzko, B. (2014a). Lower protein content in  
848 infant formula reduces BMI and obesity risk at school age: follow-up of a randomized trial.  
849 *Am J Clin Nutr* 99, 1041-1051.
- 850 World Health Organization (2002). *The optimal duration of exclusive breastfeeding: a systematic*  
851 *review* [Online]. Available:  
852 [https://apps.who.int/iris/bitstream/handle/10665/67208/WHO\\_NHD\\_01.08.pdf](https://apps.who.int/iris/bitstream/handle/10665/67208/WHO_NHD_01.08.pdf) [Accessed].
- 853 World Health Organization (2022). *World Health Organization breastfeeding recommendations*  
854 [Online]. Available: <https://www.who.int/health-topics/breastfeeding/> [Accessed 2022-06-  
855 12].
- 856 Zheng, M., Lamb, K.E., Grimes, C., Laws, R., Bolton, K., Ong, K.K., and Campbell, K. (2018).  
857 Rapid weight gain during infancy and subsequent adiposity: A systematic review and  
858 meta-analysis of evidence. *Obesity Reviews* 19, 321-332.
- 859 Ziegler, E.E. (2006). Growth of breast-fed and formula-fed infants. *Nestle Nutr Workshop Ser*  
860 *Pediatr Program* 58, 51-59; discussion 59-63.

861


A

Visit 1-2




B

Visit 2-3



C

Visit 3-4



D

Visit 4-5

